Premium
Interleukin‐1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse
Author(s) -
Abbate Antonio,
Van Tassell Benjamin W.,
Seropian Ignacio M.,
Toldo Stefano,
Robati Roshanak,
Varma Amit,
Salloum Fadi N.,
Smithson Lisa,
Dinarello Charles A.
Publication year - 2010
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1093/eurjhf/hfq017
Subject(s) - medicine , myocardial infarction , genetically engineered , heart failure , cardiology , adverse effect , gene , biochemistry , chemistry
Division of Cardiology/VCU Pauley Heart Center, Virginia Commonwealth University, 1200 East Broad Street West Hospital, 10th Floor, East Wing, Room 1041, PO Box 980281, Richmond, VA 23298-0281, USA; Victoria Johnson Center, Virginia Commonwealth University, Richmond, VA, USA; School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA; and School of Medicine, University of Colorado, Aurora, CO, USA